PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES CONTAINING AS ACTIVE INGREDIENT FUSION PROTEIN IN WHICH TISSUE PENETRATING PEPTIDE AND ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED

• 收藏
• 分享

专利权人:

发明人:

KIM SEONG BEOM,JUNG HYEI YOON,YANG SEOK WOO,KWON HYUK SANG,KANG JAE HOON

申请号：

IN201747038360

公开号：

IN201747038360A

申请日:

2017.10.30

申请国别(地区):

IN

年份:

2018

代理人:

摘要：

The present invention relates to a pharmaceutical composition for preventing and treating eye diseases containing as an active ingredient a fusion protein in which a tissue penetrating peptide and an anti vascular endothelial growth factor (anti VEGF) preparation are fused. More particularly the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases containing as an active ingredient a fusion protein in which a tissue penetrating peptide and an anti VEGF preparation are fused to a method for producing an anti VEGF preparation which overcomes resistance and has improved efficacy the method comprising the steps of transforming a host cell with a recombinant vector containing a nucleic acid sequence coding for a fusion protein in which a tissue penetrating peptide and an anti VEGF preparation are fused culturing the cell and recovering a fusion protein from the cell a method for treating eye diseases comprising administering an effective dose of the fusion protein according to the present invention to a subject in need thereof and a use for producing a preparation for treating eye diseases containing the fusion protein according to the present invention as an active ingredient. Compared to conventional anti VEGF preparations the composition according to the present invention is considered to have improved efficacy and be able to be used for treating patients having drug resistance by inhibiting various growth factors related to new blood vessels besides VEGF and by decreasing pericyte coverage. In addition since drug delivery ability into the choroid tissue is improved when performing an intraocular injection the composition can be developed into eye drops by reducing an administered dosage or extending an administration cycle and by improving ocular penetrability.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/